Videos

A thoracic oncologist, Hossein Borghaei, DO, provides an overview of the initial presentation, clinical work-up, treatment, and follow-up of a 59-year-old man with extensive-stage small cell lung cancer.

Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.

Peter Riedell, MD, discusses the effect of time to relapse in patients with mantle cell lymphoma after frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation.

Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.

Tina Cascone, MD, PhD, discusses the basis for conducting the phase 3 IMpower010 study.

David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.

The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.

Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.

Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.

The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.

Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.

Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.

Kathleen Moore, MD, discusses the safety and efficacy profile of niraparib, based on data from the phase 3 trials, PRIMA; ENGOT-OV16/NOVA, and NORA.

Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.

Jamie E. Chaft, MD, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Ursula A. Matulonis, MD, the chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, explains how the treatment paradigm of ovarian cancer has evolved with abundance of PARP inhibitors.

Carey Anders, MD, presents a case that focuses on a patient with HER2+ breast cancer and brain metastases.

Experts in the field of breast cancer review the place in therapy for margetuximab.

Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.

The panel of experts in breast cancer discusses the treatment options for a patient with systemic progression of HER2+ disease on T-DM1 and no CNS metastases.

Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.

Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.

Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.

Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.

Amit Singal, MD, discusses options after surgical resection for patients with hepatocellular carcinoma.